Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
- DOI
- 10.1186/s13058-023-01701-9
- Published
- 2023 Aug 31
- Container
- Breast cancer research : BCR
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13058-023-01701-9,
title = {Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.},
author = {Neven P and Fasching PA and Chia S and Jerusalem G and De Laurentiis M and Im SA and Petrakova K and Bianchi GV and Martín M and Nusch A and Sonke GS and De la Cruz-Merino L and Beck JT and Zarate JP and Wang Y and Chakravartty A and Wang C and Slamon DJ},
year = {2023},
journal = {Breast cancer research : BCR},
doi = {10.1186/s13058-023-01701-9},
url = {https://doi.org/10.1186/s13058-023-01701-9}
}RIS
TY - JOUR TI - Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. AU - Neven P AU - Fasching PA AU - Chia S AU - Jerusalem G AU - De Laurentiis M AU - Im SA AU - Petrakova K AU - Bianchi GV AU - Martín M AU - Nusch A AU - Sonke GS AU - De la Cruz-Merino L AU - Beck JT AU - Zarate JP AU - Wang Y AU - Chakravartty A AU - Wang C AU - Slamon DJ PY - 2023 JO - Breast cancer research : BCR DO - 10.1186/s13058-023-01701-9 UR - https://doi.org/10.1186/s13058-023-01701-9 ER -
APA
P, N., PA, F., S, C., G, J., M, D. L., SA, I., K, P., GV, B., M, M., A, N., GS, S., L, D. L. C., JT, B., JP, Z., Y, W., A, C., C, W., & DJ, S. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.. Breast cancer research : BCR. https://doi.org/10.1186/s13058-023-01701-9